Used primarily in the treatment of Cushing's disease, especially in patients who are not candidates for surgery or have not responded to prior surgical intervention. It acts as a somatostatin receptor ligand with high affinity for multiple somatostatin receptor subtypes, leading to suppression of adrenocorticotropic hormone (ACTH) secretion from pituitary tumors. This results in reduced cortisol levels, helping control the symptoms associated with hypercortisolism. Also investigated for use in acromegaly and certain neuroendocrine tumors due to its ability to inhibit hormone secretion. The trifluoroacetate salt form improves solubility and stability for clinical administration.